Compositions for prevention or treatment of acute radiation syndrome and other radiation exposure
In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.
1. A method for treating acute radiation syndrome in a subject, comprising:
administering to the subject a therapeutically effective amount of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).
2. A method for treating a subject exposed to adverse ionizing radiation, comprising:
administering to the subject a therapeutically effective amount of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).
3. The method of claim 2 , wherein the ionizing radiation comprises gamma radiation.
4. A method for treating a subject receiving radiotherapy against adverse effects of the radiotherapy, comprising:
administering to the subject a therapeutically effective amount of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG).
5. The method of claim 1 , wherein the subject has been exposed to radiation from 0.7 Gy to 50 Gy.
6. The method of claim 1 , wherein the subject is suffering from or susceptible to hematopoietic acute radiation syndrome, radiation-induced coagulopathy, gastrointestinal acute radiation syndrome, cardiovascular acute radiation syndrome, or central nervous system (CNS) acute radiation syndrome, or combination thereof.
7. The method of claim 1 , wherein the PLAG is first administered to the subject within 72 hours after radiation exposure.
8. The method of claim 1 , wherein the PLAG is administered with G-CSF.
9. The method of claim 1 , wherein the PLAG is administered with one or more selected from the group consisting of pain medicines, antiulcer drugs, antidiarrheal drugs, antibiotics, antifebriles, dietary supplements, and antioxidants.
10. The method claim 1 of wherein the subject is suffering from adverse effects of radiotherapy.
11. The method of claim 1 wherein the subject is suffering from hematopoietic acute radiation syndrome.
12. The method of claim 1 wherein the subject is suffering from radiation-induced coagulopathy.
13. The method of claim 1 wherein the subject is suffering from gastrointestinal acute radiation syndrome.
14. The method of claim 1 wherein the subject is suffering from cutaneous acute radiation syndrome.
15. The method of claim 1 wherein the subject is suffering from central nervous system (CNS) acute radiation syndrome.
16. The method of claim 1 wherein the subject is suffering from cardiovascular (CV) acute radiation syndrome.
17. The method of claim 1 wherein the subject is suffering from pulmonary dysfunction acute radiation syndrome.
18. The method of claim 1 wherein the subject has been exposed to radiation of 0.1 Gy or more.